|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
liposarcoma
metastatic breast cancer
|
|
gptkbp:ATCCode
|
L01XX41
|
|
gptkbp:CASNumber
|
253128-41-5
|
|
gptkbp:chemicalClass
|
halichondrin analog
|
|
gptkbp:developedBy
|
gptkb:Eisai_Co.,_Ltd.
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:genericName
|
gptkb:eribulin
|
|
gptkbp:hasMolecularFormula
|
C40H59NO11
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Halaven
|
|
gptkbp:indication
|
advanced breast cancer
unresectable or metastatic liposarcoma
|
|
gptkbp:KEGGID
|
D08974
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
microtubule dynamics inhibitor
|
|
gptkbp:molecularWeight
|
729.9 g/mol
|
|
gptkbp:origin
|
synthetic analog of halichondrin B from marine sponge
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
11522650
CHEMBL1201836
DB08871
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
fatigue
alopecia
peripheral neuropathy
neutropenia
|
|
gptkbp:UNII
|
1Y1FQ8V5SZ
|
|
gptkbp:bfsParent
|
gptkb:Eisai_Co.,_Ltd.
gptkb:Eisai
|
|
gptkbp:bfsLayer
|
6
|